Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Viela Bio
company
About
Viela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases.
- 101 - 250
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $282.25M
- Industries
- Biopharma,Biotechnology,Health Diagnostics,Medical,Wellness
- Founded date
- Jan 1, 2017
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Viela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases. The Company’s portfolio selectively targets shared critical pathways that are the root cause of disease. Led by a team of global leaders in inflammation and autoimmunity, Viela Bio strives to be a fully integrated biotechnology company, helping millions of patients worldwide. Viela Bio is located in Gaithersburg, Maryland.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$282.25M
Viela Bio has raised a total of
$282.25M
in funding over 2 rounds. Their latest funding was raised on
Feb 28, 2018 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 28, 2018 | Series A | $282.25M | 1 |
AstraZeneca
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Viela Bio is funded by 1 investors.
AstraZeneca
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
AstraZeneca
|
Yes | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
